AGP Picks
View all

Perspectify logo Perspectify News

Labels

Read articles from across the media landscape with news outlet bias labels for added context. Learn about labels.

Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
<![CDATA[European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC]]>

<![CDATA[European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC]]>

Cirque du Soleil performer to join ‘SHE’ Weekend on Las Vegas Strip

Cirque du Soleil performer to join ‘SHE’ Weekend on Las Vegas Strip

Summer holidays could stop PIP payments as claimants told to check

Summer holidays could stop PIP payments as claimants told to check

Morning Minute: Unplugged

Morning Minute: Unplugged

Indian passport ranking drops from 75 to 81 in latest Henley Passport Index 2026

Indian passport ranking drops from 75 to 81 in latest Henley Passport Index 2026

UK reveals important test foreign applicants must pass during British citizenship application

UK reveals important test foreign applicants must pass during British citizenship application

The Small Suffer What They Must?

The Small Suffer What They Must?

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-1 Inhibitors

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-1 Inhibitors

The rise of the public media detractor

The rise of the public media detractor

Little-known rules for PIP claimants taking holidays this summer

Little-known rules for PIP claimants taking holidays this summer

The Morning Briefing: Rally Trump Is Still My Favorite Trump

The Morning Briefing: Rally Trump Is Still My Favorite Trump

Nordic initiative signals new approach to tackling drug resistance [Advocacy Lab]

Nordic initiative signals new approach to tackling drug resistance [Advocacy Lab]

EFTA–Vietnam FTA Concluded: Business Implications for Trade, Investment, and Market Access

EFTA–Vietnam FTA Concluded: Business Implications for Trade, Investment, and Market Access

I made a tool to predict EES queues – here’s how to avoid the worst delays

I made a tool to predict EES queues – here’s how to avoid the worst delays

Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant

Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant

WHO’s Role in Stopping Cross-Border Infections

WHO’s Role in Stopping Cross-Border Infections

Việt Nam-EFTA deal set to further boost bilateral trade growth

Việt Nam-EFTA deal set to further boost bilateral trade growth

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

Vietnam-EFTA deal set to further boost bilateral trade growth

Vietnam-EFTA deal set to further boost bilateral trade growth

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.